Clinical Trial Update: Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a chemotherapy regimen followed by Rituximab and Yttrium-90 ibritumomab tiuxetan for AIDS-related Non-Hodgkin lymphoma has been withdra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aids-related Lymphoma
• Anaplastic Large Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• ibritumomab tiuxetan (ibritumomab tiuxetan)

Snippet

Sponsor: AIDS Malignancy Consortium | Conditions: AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma | Phase 2 | Status: WITHDRAWN